New Executive Director Appointed at AMIIF

The Mexican Association of Research Pharmaceutical Industries (AMIIF) announced the appointment of Erika Iliana Quevedo Chan as its new Executive Director. This strategic decision by the Board of Directors is aimed at consolidating institutional leadership, sector unity, and the Association's projection at a key moment for health in Mexico and globally. Erika Quevedo Chan previously served as General Director of the Council of Global Companies in Mexico. "It is an honor for me to join AMIIF at this new stage and contribute to the work of an Association that has been fundamental in driving innovation in health in our country," she stated. Her arrival at AMIIF seeks to promote an agenda of collaboration, innovation, investment, and access to health, strengthening strategic dialogue between the public and private sectors. "This is an industry with a clear purpose, extraordinary capabilities, and a critical role in Mexico's future," she added. She also emphasized: "I assume this responsibility with the commitment to strengthen dialogue with authorities, academia, health professionals, and all actors in the ecosystem, to contribute to the country's continued advancement in research, development, and effective access to innovative treatments." With over 20 years of experience, Erika Quevedo has distinguished herself by integrating technical and strategic visions, as well as her ability to generate agreements among diverse actors. In this context, AMIIF will concentrate its efforts on advancing in a coordinated manner along these three axes. Meanwhile, Karla Báez will continue to head the Association's Innovation and Access Commission. For his part, Jorge Luis Caridad, President of AMIIF, stated: "We are convinced that Erika Quevedo's experience, strategic vision, and articulation capacity will be key to consolidating AMIIF's role as a relevant actor in building a more innovative, competitive, and patient-centered health system." The appointment also reflects the sector's evolution towards more diverse leadership in decision-making spaces. "Health innovation only fulfills its purpose when it reaches those who need it: the patients." From her new position, Erika Quevedo will drive an agenda focused on promoting clinical research, regulatory certainty, and creating conditions that favor investment and scientific development in Mexico. The AMIIF Board of Directors thanked and recognized the work done by Karla Báez during the transition period, highlighting her leadership and commitment to ensuring institutional continuity. AMIIF underscores that the diversity of visions is consolidated as a strategic asset to face complex challenges and build more comprehensive solutions. With this move, the innovative pharmaceutical industry reaffirms its commitment to fostering an environment that promotes research, innovation, and access to new therapeutic solutions, contributing to the strengthening of the health system in Mexico.